Metabolic syndrome in pediatric obesity tracked closely with insulin resistance and adipokine imbalance

In a retrospective cohort of 429 children and adolescents with obesity, metabolic syndrome emerged in 187 participants, a prevalence of 43.6% that signals how early cardiometabolic injury can accumulate in youth. The analysis linked insulin resistance, abnormal adipokine signaling, and common obesity-related genetic variants to the likelihood of meeting pediatric criteria for metabolic syndrome. This was not a narrow endocrine exercise. It was a practical attempt to sort out which biological signals in an obese child may already be pointing toward a more dangerous metabolic trajectory.

The data came from electronic medical records collected between January 2021 and May 2025, with clinical, biochemical, endocrine, and targeted SNP genotyping information analyzed together. Fasting glucose averaged 5.3 ± 0.5 mmol/L, HbA1c averaged 5.24% ± 0.22%, and median HOMA-IR was 4.4, with an interquartile range of 2.7 to 5.7. Those values suggest a cohort in which dysglycemia had not necessarily crossed dramatic thresholds, yet metabolic stress was already measurable. In pediatric obesity, that matters because the transition from compensated insulin resistance to overt syndrome often begins before routine screening appears alarming.

One sentence captures the core clinical message: metabolic syndrome was already common in this cohort before many children would look overtly ill.

Insulin resistance carried the strongest metabolic signal

Insulin resistance was reported in 68.0% of children at Tanner stage I and 73.3% of those at Tanner stages II through V, showing that the problem was present across pubertal stages rather than confined to one developmental window. Puberty is a biologically volatile period for insulin action, with transient physiologic resistance layered on top of adiposity-driven metabolic strain. When that normal pubertal shift is amplified by obesity, hepatic glucose handling, lipotoxicity, and compensatory hyperinsulinemia can all intensify at once.

Elevated HOMA-IR was strongly associated with metabolic syndrome, with an odds ratio of 2.89 and a 95% confidence interval of 1.71 to 4.99, with P less than 0.001. In clinical terms, that places insulin resistance at the center of risk stratification rather than as a background laboratory curiosity. Children who are already hyperinsulinemic may be progressing toward clustered cardiometabolic abnormalities long before they meet adult-style criteria for diabetes. The bedside consequence is straightforward: a fasting insulin resistance pattern in an obese child deserves more attention than weight alone would suggest.

Leptin and adiponectin pointed in opposite directions

The adipokine profile followed the expected pathophysiology of excess adipose tissue, but the associations were strong enough to matter. Leptin was positively associated with metabolic syndrome risk, with an odds ratio of 1.32 and a 95% confidence interval of 1.02 to 1.70, while adiponectin was inversely associated, with an odds ratio of 0.63 and a 95% confidence interval of 0.49 to 0.80. Elevated leptin in obesity often reflects leptin resistance rather than effective satiety signaling, and the result is persistent hypothalamic and peripheral metabolic dysregulation. Low adiponectin, by contrast, removes a protective brake on inflammation, insulin sensitivity, and vascular homeostasis.

Viewed together, these signals fit the biology of adipose tissue dysfunction. The tissue is not simply storing surplus energy; it is secreting hormones that can either buffer or amplify metabolic injury. A child with obesity, high leptin, and low adiponectin is likely moving through a state of chronic endocrine miscommunication in which insulin resistance becomes easier to sustain and harder to reverse.

FTO and MC4R variants added a genetic layer to clinical risk

Genetic susceptibility was not treated as an abstract background factor. Carriage of risk alleles in FTO and MC4R independently predicted metabolic syndrome, with odds ratios of 1.88 and 1.71, respectively. Those associations fit the broader role of these genes in appetite regulation, energy balance, and obesity biology. FTO has long been linked to adiposity and metabolic phenotypes, while MC4R variation can alter central appetite pathways and weight regulation. In a child already struggling with excess adiposity, inherited vulnerability may help explain why two patients with similar body mass do not share the same metabolic trajectory.

The study also examined LEPR rs1137101, although the abstract did not provide a parallel effect estimate for that variant. Even without overreading the result, the inclusion of leptin-receptor biology reinforces the same theme: appetite signaling and energy regulation are tightly bound to downstream metabolic risk. Pediatric obesity is not a single-pathway disorder, and the genotype data in this cohort point to that complexity without requiring speculative embellishment.

A combined model reached acceptable discrimination, but not certainty

When endocrine and genetic variables were combined, the model achieved an area under the receiver operating characteristic curve of 0.751. In practical terms, that is an acceptable level of discrimination, suggesting the profile can separate higher-risk from lower-risk children better than chance and better than any single marker used in isolation. It does not create a stand-alone diagnostic tool. It does, however, support the idea that metabolic risk in pediatric obesity is best captured by a layered assessment rather than by body size alone.

This is the kind of model that may eventually help clinicians identify which children need earlier and more intensive metabolic surveillance. A child with obesity, elevated HOMA-IR, adverse adipokine levels, and risk alleles in FTO or MC4R may deserve closer follow-up for dysglycemia, dyslipidemia, and blood pressure abnormalities, even when routine screening seems only mildly abnormal. The physiology is already in motion by the time the syndrome becomes obvious.

The study’s retrospective design limits causal inference, and the abstract does not provide outcome data beyond model discrimination. Even so, the signal is clinically coherent: endocrine dysfunction and common obesity-related genetic variants were independently associated with pediatric metabolic syndrome, and the combined model separated risk with moderate accuracy. Whether such profiling can improve earlier intervention in routine pediatric practice will depend on prospective validation and on whether a more precise metabolic map changes decisions at the bedside.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by JAMA (Journal of the American Medical Association).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA